REZOLUTE INC (RZLT)

US76200L3096 - Common Stock

2.64  +0.08 (+3.13%)

After market: 2.57 -0.07 (-2.65%)

News Image
4 days ago - BusinessInsider

RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rezolute (NASDAQ:RZLT) just reported results for the third quarter of 2024.Rezo...

News Image
4 days ago - InvestorPlace

RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024

RZLT stock results show that Rezolute missed analyst estimates for earnings per share the third quarter of 2024.

News Image
4 days ago - Rezolute, Inc.

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected...

News Image
a month ago - InvestorPlace

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.

News Image
2 months ago - Rezolute, Inc.

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)

News Image
2 months ago - Rezolute, Inc.

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor...

News Image
3 months ago - Rezolute, Inc.

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in...

News Image
4 months ago - Seeking Alpha

Rezolute appoints Daron Evans as CFO (NASDAQ:RZLT)

Rezolute (RZLT) has announced the addition of Daron Evans, to its leadership team as CFO as well as the grant of share options as a material inducement for his

News Image
4 months ago - Rezolute, Inc.

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing...

News Image
4 months ago - Rezolute, Inc.

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing...

News Image
5 months ago - Rezolute, Inc.

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Plans to report topline data mid-second quarter 2024

News Image
5 months ago - Rezolute, Inc.

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Plans to report topline data mid-second quarter 2024...

News Image
6 months ago - Newsfile

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday...

News Image
6 months ago - Rezolute, Inc.

Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day

REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing...

News Image
6 months ago - Rezolute, Inc.

Rezolute Reports First Quarter Fiscal 2024 Results

REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing...

News Image
7 months ago - Rezolute, Inc.

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism

News Image
7 months ago - Rezolute, Inc.

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

REDWOOD CITY, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing...

News Image
8 months ago - Rezolute, Inc.

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

News Image
8 months ago - Rezolute, Inc.

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023